Mod­er­na es­tab­lish­es pub­lic health-fo­cused char­i­ty; FDA ap­proves As­traZeneca di­a­betes drug for pe­di­atric use

Noubar Afeyan

To help pro­mote pub­lic health and health­care in un­der­served ar­eas of the world, Mod­er­na will es­tab­lish a char­i­ty with a $50 mil­lion en­dow­ment.

The Cam­bridge, MA-based com­pa­ny an­nounced the board of di­rec­tors’ ap­proval Thurs­day. The foun­da­tion will fo­cus on “char­i­ta­ble, sci­en­tif­ic and ed­u­ca­tion­al en­deav­ors” with an em­pha­sis on pro­mot­ing pub­lic health and the ac­cess to health­care, the press re­lease said. The foun­da­tion will start op­er­a­tions once its sta­tus as a 501(c)(3) is ap­proved.

“We view Mod­er­na’s work as on­ly just be­gin­ning. On be­half of our grow­ing team, part­ners and share­hold­ers, we are de­ter­mined to ex­tend Mod­er­na’s so­ci­etal im­pact through the for­ma­tion of the Mod­er­na Char­i­ta­ble Foun­da­tion,” Mod­er­na co-founder Noubar Afeyan said in a press re­lease. “Hav­ing ex­pe­ri­enced the pos­i­tive im­pact such char­i­ta­ble foun­da­tions can have on those in need, I look for­ward to the con­tri­bu­tions that we will make.”

By­dure­on BCise ap­proved for use in ado­les­cents 10 and old­er by FDA

As­traZeneca’s once-week­ly in­jectable, ex­tend­ed re­lease treat­ment for type 2 di­a­betes will now be avail­able for use in chil­dren, the com­pa­ny an­nounced Fri­day.

Mene Pan­ga­los

By­dure­on BCise has been ap­proved for the use in chil­dren 10 years and old­er by the FDA to im­prove glycemic con­trol. The ap­proval is the first for a glucagon-like pep­tide-1 re­cep­tor against GLP-1 RA.

A steady rise in glob­al obe­si­ty num­bers since the 1990s makes the ap­proval of By­dure­on that much more im­por­tant, As­traZeneca said in the press re­lease.

“This de­ci­sion is an im­por­tant mile­stone for the care of this younger pa­tient pop­u­la­tion by pro­vid­ing a con­ve­nient, once-week­ly treat­ment op­tion,” R&D chief Mene Pan­ga­los said in a press re­lease. “The Phase III da­ta that sup­port­ed this ap­proval demon­strat­ed the safe­ty and tol­er­a­bil­i­ty of ex­e­natide ex­tend­ed-re­lease in younger pa­tients was sim­i­lar to the proven safe­ty pro­file of this med­i­cine in adults.”

The drug was first ap­proved in the US in 2017, and by Eu­ro­pean reg­u­la­tors in Au­gust 2018.

The Phase III — dubbed BCB114 — was a 24-week ran­dom­ized place­bo-con­trolled tri­al with type 2 di­a­betes pa­tients treat­ed with ei­ther on­ly di­et and ex­er­cise or with a com­bi­na­tion of an­tidi­a­bet­ic agents and in­sulin. A tri­al for pa­tients younger than 10 has not yet been stud­ied.

Biotech Half­time Re­port: Af­ter a bumpy year, is biotech ready to re­bound?

The biotech sector has come down firmly from the highs of February as negative sentiment takes hold. The sector had a major boost of optimism from the success of the COVID-19 vaccines, making investors keenly aware of the potential of biopharma R&D engines. But from early this year, clinical trial, regulatory and access setbacks have reminded investors of the sector’s inherent risks.

RBC Capital Markets recently surveyed investors to take the temperature of the market, a mix of specialists/generalists and long-only/ long-short investment strategies. Heading into the second half of the year, investors mostly see the sector as undervalued (49%), a large change from the first half of the year when only 20% rated it as undervalued. Around 41% of investors now believe that biotech will underperform the S&P500 in the second half of 2021. Despite that view, 54% plan to maintain their position in the market and 41% still plan to increase their holdings.

Covid-19 vac­cine boost­ers earn big thumbs up, but Mod­er­na draws ire over world sup­ply; What's next for Mer­ck’s Covid pill?; The C-suite view on biotech; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

You may remember that at the beginning of this year, Endpoints News set a goal to go broader and deeper. We are still working towards that, and are excited to share that Beth Snyder Bulik will be joining us on Monday to cover all things pharma marketing. You can sign up for her weekly Endpoints MarketingRx newsletter in your reader profile.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 119,800+ biopharma pros reading Endpoints daily — and it's free.

No­var­tis de­vel­op­ment chief John Tsai: 'We go deep in the new plat­form­s'

During our recent European Biopharma Summit, I talked with Novartis development chief John Tsai about his experiences over the 3-plus years he’s been at the pharma giant. You can read the transcript below or listen to the exchange in the link above.

John Carroll: I followed your career for quite some time. You’ve had more than 20 years in big pharma R&D and you’ve obviously seen quite a lot. I really was curious about what it was like for you three and a half years ago when you took over as R&D chief at Novartis. Obviously a big move, a lot of changes. You went to work for the former R&D chief of Novartis, Vas Narasimhan, who had his own track record there. So what was the biggest adjustment when you went into this position?

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Amit Etkin, Alto Neuroscience CEO (Alto via Vimeo)

A star Stan­ford pro­fes­sor leaves his lab for a start­up out to re­make psy­chi­a­try

About five years ago, Amit Etkin had a breakthrough.

The Stanford neurologist, a soft-spoken demi-prodigy who became a professor while still a resident, had been obsessed for a decade with how to better define psychiatric disorders. Drugs for depression or bipolar disorder didn’t work for many patients with the conditions, and he suspected the reason was how traditional diagnoses didn’t actually get at the heart of what was going on in a patient’s brain.

Susan Galbraith, Executive VP, Oncology R&D, AstraZeneca

As­traZeneca on­col­o­gy R&D chief Su­san Gal­braith: 'Y­ou're go­ing to need or­thog­o­nal com­bi­na­tion­s'


Earlier in the week we broadcast our 4th annual European Biopharma Summit with a great lineup of top execs. One of the one-on-one conversations I set up was with Susan Galbraith, the oncology research chief at AstraZeneca. In a wide-ranging discussion, Galbraith reviewed the cancer drug pipeline and key trends influencing development work at the pharma giant. You can watch the video, above, or stick with the script below. — JC

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Roche's Tecen­triq cross­es the fin­ish line first in ad­ju­vant lung can­cer, po­ten­tial­ly kick­ing off gold rush

While falling behind the biggest PD-(L)1 drugs in terms of sales, Roche has looked to carve out a space for its Tecentriq with a growing expertise in lung cancer. The drug will now take an early lead in the sought-after adjuvant setting — but competitors are on the way.

The FDA on Friday approved Tecentriq as an adjuvant therapy for patients with Stage II-IIIA non small cell lung cancer with PD-(L)1 scores greater than or equal to 1, making it the first drug of its kind approved in an early setting that covers around 40% of all NSCLC patients.

FDA ad­comm to de­cide on mol­nupi­ravir EUA; Can­cer at­las un­veils new po­ten­tial drug tar­get

The FDA has another adcomm coming down the pipeline — this time on Covid-19 oral antiviral molnupiravir.

The federal agency’s advisory committee will meet on November 30th to go over Merck and Ridgeback’s EUA request for their investigational antiviral drug, and discuss the available data supporting its use in Covid-19 patients.

This comes two weeks after Merck claimed that their antiviral pill reduced the chance that newly diagnosed Covid-19 patients would be hospitalized or die by 50%. The pharma made the announcement after interim data on 775 patients in their clinical trial showed the antiviral’s potential.

Tillman Gerngross, Adagio CEO

Q&A: Till­man Gern­gross ex­plains why his Covid mAb will have an edge over an al­ready crowd­ed field

If anyone knows about monoclonal antibodies, it’s serial entrepreneur, Adimab CEO, and Dartmouth professor of bioengineering Tillman Gerngross.

Even the name of Gerngross’ new antibody startup Adagio Therapeutics is meant to reflect his vision behind the development of his Covid-19 mAb: slowly, he said, explaining that “everyone else, whether it’s Regeneron, Lilly, or AstraZeneca, Vir, they all valued speed over everything.”

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

FDA ad­comm votes unan­i­mous­ly in sup­port of a J&J Covid-19 boost­er two months af­ter one-dose shot

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Friday voted 19-0 in favor of authorizing a second shot of J&J’s Covid-19 vaccine to follow at least two months after the initial dose.

Regulators don’t have to follow VRBPAC’s recommendation, but they almost always do. Considering that the CDC’s advisory committee has already been set to review the expanded EUA, VRBPAC’s recommendation is likely to be adopted.